Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic agents.
Korn
Edward L
EL
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D012107:Research Design / Q000592:standards
D000970:Antineoplastic Agents